A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

NCT05564039 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

282

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Tirzepatide
DRUG: Dulaglutide

Sponsor

Eli Lilly and Company